



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel.: 022-2407 2249 / 2401 9025 (30 Lines)
Fax: 022-2407 3462 / 2407 0144
Email: audit@artidrugs.com
website: www.artidrugs.com
CIN No.: L37060MH1984PLC055433

AARTI DRUGS LIMITED					
STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE, 2015					
PART I (Rs. In Lacs except for share data)					
Sr. No.	PARTICULARS	Quarter Ended			Financial Year Ended
		30th Jun, 2015 (Audited)	31st Mar, 2015 (Audited)	30th Jun, 2014 (Audited)	31st Mar, 2015 (Audited)
1	Income from Operations				
	(a) Gross Sales / Income from Operations	28,640	30,067	27,877	1,16,994
	Less: Excise Duty & Sales Tax	2,310	2,306	1,917	8,546
	(a) Net Sales / Income from Operations (Net Of Excise Duty & Sales Tax)	26,329	27,761	25,960	1,08,448
	(b) Other Operating Income	38	76	10	274
	Total income from operations (net)	26,367	27,837	25,970	1,08,722
2	Expenditure				
	(a) Cost of materials consumed	18,979	15,630	16,709	67,844
	(b) Purchase of stock-in-trade	971	1,175	3,195	8,699
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(2,481)	2,139	(2,052)	(2,358)
	(d) Employee benefits expense	994	1,024	872	3,730
	(e) Depreciation and Amortisation Expense	867	809	741	3,066
	(f) Other expenses	3,553	3,578	3,261	13,911
	Total expenses	22,883	24,355	22,725	94,893
3	Profit from Operations before Other Income, finance costs and exceptional items (1-2)	3,484	3,482	3,245	13,829
4	Other Income	-	0	-	65
5	Profit from ordinary activities before finance cost and exceptional items (3+4)	3,484	3,482	3,245	13,894
6	Finance costs (interest)	1,029	976	982	3,888
7	Profit from ordinary activities after finance cost but before Exceptional Items (5-6)	2,455	2,506	2,262	10,006
8	Exceptional Items	-	-	-	-
9	Profit from Ordinary Activities before Tax (7-8)	2,455	2,506	2,262	10,006
10	Tax Expenses	750	620	539	2,247
	Provision for Taxation - Current	610	528	480	2,100
	- MAT Credit Entitlement	-	(48)	(21)	(100)
	- Earlier year	-	-	-	(153)
	Provision for Deferred Taxation	140	140	80	400
11	Net profit from ordinary Activities after Tax (9-10)	1,705	1,886	1,724	7,760
12	Extraordinary items	-	-	-	-
13	Net Profit for the Period (11+12)	1,705	1,886	1,724	7,760
14	Paid-up Equity Share Capital of Rs. 10/- each.	2,422	2,422	1,211	2,422
15	Reserves & Surplus (excluding revaluation reserves)				27,949
16	Earning per share				
	Diluted E P S (in Rs.) (of Rs. 10 /- each) (not annualised)				
	(a) Basic & Diluted (before extraordinary items)	7.04	7.79	7.12	32.04
	(b) Basic & Diluted (after extraordinary items)	7.04	7.79	7.12	32.04

Regd. Office : Plot No. N-198, MIDC, Tarapur, Tal-Palghar, Dist. Palghar - 401 506. (MH)



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel.: 022-2407 2249 / 2401 9025 (30 Lines)
Fax: 022-2407 3462 / 2407 0144
Email: audit@aartidrugs.com
website: www.aartidrugs.com
CIN No.: L37060MH1984PLC055433

PART II

A		PARTICULARS OF SHAREHOLDING			
1	Public shareholding				
	-Number of Shares	96,95,363	96,62,736	48,52,768	96,62,736
	-Percentage of Total Shareholding	40.04	39.90	40.08	39.90
2	Promoters & Promoter Group shareholding				
a)	Pledged/Encumbered				
	- Number of Shares	Nil	Nil	Nil	Nil
	-Percentage of shares(as a % of the total shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil
	-Percentage of shares(as a % of the total Share capital of the company)	Nil	Nil	Nil	Nil
b)	Non-encumbered				
	- Number of Shares	1,45,21,737	1,45,54,364	72,55,782	1,45,54,364
	-Percentage of shares(as a % of the total Shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00
	-Percentage of shares(as a % of the total Share capital of the company)	59.96	60.10	59.92	60.10
		Qtr Ended 30th June, 2015			
B	INVESTOR COMPLAINTS				
	Pending at the beginning of the quarter		0		
	Received during the quarter		2		
	Disposed of during the quarter		2		
	Remaining unresloved at the end of the quarter		0		

Notes:

1

The above results, reviewed by the Audit Committee, have been taken on record by the Board of Directors at their meeting held on 31st July, 2015

2 Company is operating as a Single Segment Company, engaged in Pharmaceuticals Business.

3 Figures for the previous period have been regrouped or rearranged wherever necessary.

For and on behalf of the Board
For AARTI DRUGS LIMITED

HARSHIT M. SAVLA
(JT. MANAGING DIRECTOR)

Place: Mumbai
Date: 31st July, 2015



Auditor's Report on Quarterly Financial Results of Aarti Drugs Limited Pursuant to the Clause 41 of the Listing Agreement

To
Board of Directors of Aarti Drugs Limited

We have audited the quarterly financial results of Aarti Drugs Limited for the quarter ended 30th June, 2015 attached herewith, being submitted by the Company pursuant to the requirement of clause 41 of the Listing Agreement except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. These quarterly financial results have been prepared on the basis of the interim financial statements and annual financial results have been prepared on the basis of the annual financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard (AS) 25, Interim Financial Reporting, specified under section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatements. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.





In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results:

- (i) are presented in accordance with the requirements of clause 41 of the Listing Agreement in this regard; and
- (ii) give a true and fair view of the net profit and other financial information for the quarter ended 30th June 2015.

Further, we also report that we have, on the basis of the books of account and other records and information and explanations given to us by the management, verified the number of shares as well as percentage of shareholdings in respect of aggregate amount of non promoter shareholdings, as furnished by the company in terms of clause 35 of the Listing Agreement and found the same to be correct.

For GOKHALE & SATHE
CHARTERED ACCOUNTANTS



Tejas Parikh
CA TEJAS PARIKH
PARTNER
M.No. 123215

Firm Registration No.: 103264W

Place: Mumbai,

Dated: July 31, 2015